Define the clinical question precisely
“Earlier detection” sounds attractive, but earlier than what, in which animals, and what should the veterinarian do with the result? A useful test begins with a defined population and decision.
For example, a screening test, confirmatory test, monitoring assay and prognostic tool have different performance expectations. The intended use determines which false positives and false negatives are most costly.
Analytical performance is only the first layer
Precision, reproducibility, detection limits and interference matter, but clinical validation asks whether performance holds in the target population. Prevalence also affects how a result should be interpreted in practice.
Startups should avoid presenting sensitivity and specificity without explaining the study design, comparison method and patient population. Investors should ask for the confusion matrix, not only the headline percentage.
Turnaround time is part of diagnostic value
A moderately better result that returns after the treatment decision may have less value than a good result available during the visit. Sample handling, shipping, instrument maintenance and repeat-test rates belong in commercial diligence.
Point-of-care systems trade laboratory centralization for clinic workflow. Reference-lab products can leverage established logistics but must justify their place in the test menu.
The final metric is changed behavior
The strongest evidence shows what happens after the result: a medication is started or avoided, a referral is prioritized, a procedure is scheduled, or a patient is monitored differently.
Companies that connect test performance to clinical utility can communicate more clearly with veterinarians, regulators, partners and investors.
Primary resources
- FDA – Animal & Veterinary
- USDA APHIS – Veterinary Biologics